Agios Pharmaceuticals, Inc. (AGIO): Revenue
$54.03M
Year ended 2025-12-31
$98.34M
Trailing 12 months to 2026-06-30
+56.0%
3-year compound annual growth
-0.9%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.03M | +48.0% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $36.50M | +36.1% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $26.82M | +88.4% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $14.24M | n/a | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $0 | -100.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $117.91M | +24.9% | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | $94.39M | +119.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $43.01M | -38.5% | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $69.89M | +18.2% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $59.12M | -9.5% | 2018-02-14, From 2015-01-01 |
| 2014-12-31 | $65.36M | +155.8% | 2015-02-24, From 2014-01-01 |
| 2013-12-31 | $25.55M | +1.8% | 2015-02-24, From 2013-01-01 |
| 2012-12-31 | $25.11M | +15.0% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $21.84M | n/a | 2014-03-18, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $54.03M | +48.0% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $53.74M | n/a |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $54.35M | +8.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $55.23M | -43.9% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $51.95M | -18.5% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $49.80M | +60.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $48.47M | -57.7% |
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
Compare AGIO, QTTB, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗